Charlie McLeod
Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis: A systematic review
McLeod, Charlie; Wood, Jamie; Schultz, Andr�; Norman, Richard; Smith, Sherie; Blyth, Christopher C.; Webb, Steve; Smyth, Alan R.; Snelling, Thomas L.
Authors
Jamie Wood
Andr� Schultz
Richard Norman
SHERIE SMITH sherie.smith@nottingham.ac.uk
Cochrane Systematic Reviewer
Christopher C. Blyth
Steve Webb
Alan R. Smyth
Thomas L. Snelling
Abstract
Background: There is no consensus about which outcomes should be evaluated in studies of pulmonary exacerbations in people with cystic fibrosis (CF). Outcomes used for evaluation should be meaningful; that is, they should capture how people feel, function or survive and be acknowledged as important to people with CF, or should be reliable surrogates of those outcomes. We aimed to summarise the outcomes and corresponding endpoints which have been reported in studies of pulmonary exacerbations, and to identify those which are most likely to be meaningful. Methods: A PROSPERO registered systematic review (CRD42020151785) was conducted in Medline, Embase and Cochrane from inception until July 2020. Registered trials were also included. Results: 144 studies met the inclusion criteria. A wide range of outcomes and corresponding endpoints were reported. Death, QoL and many patient-reported outcomes are likely to be meaningful as they directly capture how people feel, function or survive. Forced expiratory volume in 1-second [FEV1] is a validated surrogate of risk of death and reduced QoL. The extent of structural lung disease has also been correlated with lung function, pulmonary exacerbations and risk of death. Since no evidence of a correlation between airway microbiology or biomarkers with clinically meaningful outcomes was found, the value of these as surrogates was unclear. Conclusions: Death, QoL, patient-reported outcomes, FEV1, and structural lung changes were identified as outcomes that are most likely to be meaningful. Development of a core outcome set in collaboration with stakeholders including people with CF is recommended.
Citation
McLeod, C., Wood, J., Schultz, A., Norman, R., Smith, S., Blyth, C. C., …Snelling, T. L. (2020). Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis: A systematic review. Journal of Cystic Fibrosis, 19(6), 858-867. https://doi.org/10.1016/j.jcf.2020.08.015
Journal Article Type | Review |
---|---|
Acceptance Date | Aug 25, 2020 |
Online Publication Date | Nov 13, 2020 |
Publication Date | 2020-11 |
Deposit Date | Nov 14, 2020 |
Publicly Available Date | Nov 14, 2021 |
Journal | Journal of Cystic Fibrosis |
Print ISSN | 1569-1993 |
Electronic ISSN | 1873-5010 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 19 |
Issue | 6 |
Pages | 858-867 |
DOI | https://doi.org/10.1016/j.jcf.2020.08.015 |
Keywords | Pediatrics, Perinatology, and Child Health; Pulmonary and Respiratory Medicine |
Public URL | https://nottingham-repository.worktribe.com/output/5040298 |
Publisher URL | https://www.cysticfibrosisjournal.com/article/S1569-1993(20)30829-8/fulltext |
Related Public URLs | https://www.sciencedirect.com/science/article/abs/pii/S1569199320308298 |
Files
Outcomes And Endpoints SR V1.2 Clean Copy
(852 Kb)
PDF
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search